EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Model-informed development of bacteriophage therapy: bridging in vitro and in vivo efficacy against multidrug-resistant Pseudomonas aeruginosa

Jun Seok Cha iD, Kyungnam Kim, Hwa Jeong You, Dasom Kim, Hyun Hee Park, SuJin Heo, Choon Ok Kim, Byung Hak Jin, Dongeun Yong iD, Dongwoo Chae iD

mSystems · 2025

DOI: 10.1128/msystems.01384-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mSystems, 2025. Verfasst von Jun Seok Cha und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Yonsei University, Seodaemun-gu, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Phage Therapy, Pseudomonas Infections, Drug Resistance, Multiple, Bacterial. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Health Industry Development Institute, Brain Korea 21 FOUR Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bacteriophages are emerging as promising alternatives to antibiotics for multidrug-resistant (MDR) infections. However, their unique pharmacokinetic and pharmacodynamic (PKPD) properties arising from host-dependent amplification present challenges for dose selection and clinical translation. Here, we present a mechanistic PKPD model informed by in vitro kinetic assays and in vivo mouse studies of phage therapy targeting MDR Pseudomonas aeruginosa . The model extends the classical predator-prey model by addressing dormancy-related bacterial persistence and partitioning bacterial subpopulations based on phage susceptibility profiles. Simulations revealed a non-monotonous dose-exposure curve driven by dose-dependent reduction of phage replication and the importance of cross-resistance in selecting optimal phage cocktails. In vivo , host immunity was identified as a crucial component in inhibiting bacterial regrowth, with bistable outcomes dependent on initial bacterial load and immune competence. Dose-ranging simulations under varying immune statuses suggest that long-term bacterial load is solely determined by host immune function. However, higher doses transiently reduce bacterial load to a greater extent and thereby suppress immune activation. In immunocompetent hosts, phage cocktails can enhance maximal bacterial load reduction when administered at doses higher than a critical threshold. In conclusion, our PKPD framework enables optimal selection of phage cocktails and dosing regimens, supports rational design of first-in-human trials of phage therapy, and potentially advances model-informed drug development for replication-competent biologics. IMPORTANCE In this study, we construct an integrative model of phage-bacteria dynamics and investigate whether its calibration to in vitro kinetic assay data can inform the rational design of phage therapy regimens and cocktails. Our findings demonstrate a dose range within which lower phage doses yield higher long-term exposure, presenting a fundamentally different framework for dose optimization. Analysis of phage cocktails reveals that combining phages with low cross-resistance delays the regrowth of phage-resistant bacteria in vitro . The extended in vivo model elucidates key differences between in vitro and in vivo outcomes and highlights the importance of the host’s immune response in suppressing the growth of phage-resistant bacteria. Phage cocktails to combat phage resistance are therefore of less importance in immune-competent individuals but can enhance bacterial killing when administered at sufficiently high doses. We propose that this modeling framework holds potential for model-informed drug development by quantitatively characterizing bacteria-phage dynamics using preclinical data. Furthermore, it may facilitate the interpretation of in vivo therapeutic outcomes through a mechanistic understanding derived from in vitro observations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pseudomonas aeruginosaPhage TherapyPseudomonas InfectionsDrug Resistance, Multiple, BacterialBacteriophagesModels, BiologicalAnimalsMicePseudomonas PhagesHumans

Stichwörter der Autor:innen

Pseudomonas aeruginosabacteriophage therapybacteriophagescomputational biologymathematical modelingmodel-informed drug developmentphage cocktail optimizationpharmacokinetics pharmacodynamicspredator-prey dynamicsquantitative systems pharmacology

Autor:innen und Institutionen

  • Department of Pharmacology, Yonsei University, Seodaemun-gu, Seoul, Republic of Korea.
  • Department of Pharmacology, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Republic of Korea.
  • Microbiotix Co., Ltd, Seoul, Republic of Korea.
  • Department of Clinical Pharmacology, Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea.
  • Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, Republic of Korea.

ORCID-Profile: Jun Seok Cha, Dongeun Yong, Dongwoo Chae

Förderung

  • Korea Health Industry Development Institute
  • Brain Korea 21 FOUR Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea

Zitieren

APA

Cha, J. S., Kim, K., You, H. J., Kim, D., Park, H. H., Heo, S., Kim, C. O., Jin, B. H., Yong, D., & Chae, D. (2025). Model-informed development of bacteriophage therapy: bridging in vitro and in vivo efficacy against multidrug-resistant Pseudomonas aeruginosa. mSystems. https://doi.org/10.1128/msystems.01384-25

Vancouver

Cha JS, Kim K, You HJ, Kim D, Park HH, Heo S, et al. Model-informed development of bacteriophage therapy: bridging in vitro and in vivo efficacy against multidrug-resistant Pseudomonas aeruginosa. mSystems. 2025. doi:10.1128/msystems.01384-25

BibTeX
@article{Cha2025,
  author = {Cha, Jun Seok and Kim, Kyungnam and You, Hwa Jeong and Kim, Dasom and Park, Hyun Hee and Heo, SuJin and Kim, Choon Ok and Jin, Byung Hak and Yong, Dongeun and Chae, Dongwoo},
  title = {Model-informed development of bacteriophage therapy: bridging in vitro and in vivo efficacy against multidrug-resistant Pseudomonas aeruginosa},
  journal = {mSystems},
  year = {2025},
  doi = {10.1128/msystems.01384-25}
}
Kostenlos starten →